Several studies have recently revealed MYC/BCL2/BCL6 rearrangements and TP53 mutations as independent indicators of prognosis in patients with DLBCL treated with standard chemotherapy. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.